Diabetic Kidney Disease (DKD)
16
3
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Rubix LS Diabetic Kidney Disease (DKD) Registry Study
Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure
Mesenchymal Stem Cells for Chronic Kidney Diseases
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
Remote Ischemic Conditioning for the Treatment of Diabetic Kidney Disease
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases